The revised guidelines also will lead to more than $20 million in extra health care costs, the research shows.

Phase 3 trial results demonstrate that bepirovirsen significantly increases the proportion of patients achieving functional cure compared with placebo.

HBV reactivation risk rises after rituximab in CHB patients post-antiviral withdrawal. Learn more about relapse timing and ...

—In a global study of 614 adults with chronic hepatitis B (CHB), treatment compliance was affected by obstacles such as physical functioning and healthcare service accessibility, making clear the need ...

CNW/ - GSK today announced that it has filed a new drug submission for bepirovirsen for regulatory review in Canada.

Hepatitis B testing can show whether you have a current or past HBV infection and whether you have antibodies from a hepatitis B vaccine. Hepatitis B is a viral infection caused by the hepatitis B ...

Whether hepatitis resolves depends on the type and whether a person receives treatment. Hepatitis A usually resolves without medications, and while sometimes hepatitis B and C may last only a few ...

Global efforts to combat viral hepatitis are delivering measurable progress in reducing infections and deaths, but the ...

The World Health Organization (WHO) released a new report on hepatitis today, marking the World Hepatitis Summit. Since 2015, ...

The World Health Organization has issued its first-ever hepatitis B guidelines that outline how to determine who needs treatment, what medicines to use and how to monitor patients long-term. The ...

A study presented at The International Liver Congress 2016 in Barcelona, Spain, revealed a link between long-term oral nucleos(t)ide analogues and a higher risk of colorectal and cervical cancer in ...